S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:SYRS

Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis

$5.35
-0.49 (-8.39%)
(As of 04:00 PM ET)
Today's Range
$5.15
$5.90
50-Day Range
$5.84
$7.75
52-Week Range
$2.09
$8.17
Volume
317,751 shs
Average Volume
198,896 shs
Market Capitalization
$112.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.33

Syros Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
130.1% Upside
$12.33 Price Target
Short Interest
Bearish
9.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.38mentions of Syros Pharmaceuticals in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.73) to ($3.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.17 out of 5 stars

Medical Sector

178th out of 938 stocks

Pharmaceutical Preparations Industry

71st out of 433 stocks

SYRS stock logo

About Syros Pharmaceuticals Stock (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

SYRS Stock Price History

SYRS Stock News Headlines

Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Syros Pharmaceuticals earnings preview: what Wall Street is expecting
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
SYRS Apr 2024 10.000 call
SYRS Jul 2024 2.500 call
Syros Pharmaceuticals, Inc. (SYRS)
SYRS Mar 2024 7.500 put
Syros Pharmaceuticals Inc.
See More Headlines
Receive SYRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/05/2021
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SYRS
Fax
N/A
Employees
117
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.33
High Stock Price Target
$15.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+130.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-94,650,000.00
Pretax Margin
-1,193.45%

Debt

Sales & Book Value

Annual Sales
$14.88 million
Book Value
$6.32 per share

Miscellaneous

Free Float
18,865,000
Market Cap
$112.94 million
Optionable
Optionable
Beta
1.79
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Richard A. Young Ph.D. (Age 70)
    Scientific Founder, Member of Scientific Advisory Board & Director
    Comp: $108.37k
  • Dr. David A. Roth M.D. (Age 61)
    Chief Medical Officer
    Comp: $679.52k
  • Mr. Conley Chee (Age 54)
    CEO, President & Director
  • Dr. James E. Bradner M.D. (Age 52)
    Founder
  • Dr. Nathanael S. Gray Ph.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Jason Haas (Age 56)
    Chief Financial Officer
    Comp: $457.22k
  • Ms. Karen Hunady M.S.
    Director of Corporate Communications & Investor Relations
  • Mr. Gerald E. Quirk Esq. (Age 56)
    J.D., Chief Legal Officer & Head of Business Development
    Comp: $127.07k
  • Ms. Lisa Roberts
    Vice President of Human Resources
  • Ms. Kristin Stephens (Age 51)
    Chief Development Officer

SYRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Syros Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SYRS shares.
View SYRS analyst ratings
or view top-rated stocks.

What is Syros Pharmaceuticals' stock price target for 2024?

2 Wall Street analysts have issued 12 month target prices for Syros Pharmaceuticals' stock. Their SYRS share price targets range from $7.00 to $15.00. On average, they expect the company's share price to reach $12.33 in the next year. This suggests a possible upside of 130.1% from the stock's current price.
View analysts price targets for SYRS
or view top-rated stocks among Wall Street analysts.

How have SYRS shares performed in 2024?

Syros Pharmaceuticals' stock was trading at $7.79 at the beginning of the year. Since then, SYRS stock has decreased by 31.2% and is now trading at $5.36.
View the best growth stocks for 2024 here
.

Are investors shorting Syros Pharmaceuticals?

Syros Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,740,000 shares, an increase of 31.8% from the February 29th total of 1,320,000 shares. Based on an average trading volume of 212,500 shares, the short-interest ratio is currently 8.2 days. Currently, 9.6% of the shares of the stock are short sold.
View Syros Pharmaceuticals' Short Interest
.

When is Syros Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our SYRS earnings forecast
.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) released its quarterly earnings results on Friday, November, 5th. The company reported ($4.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.40) by $0.30. The business earned $5.70 million during the quarter, compared to analysts' expectations of $5.10 million. During the same period in the previous year, the company earned ($4.30) earnings per share.

When did Syros Pharmaceuticals' stock split?

Shares of Syros Pharmaceuticals reverse split on Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

When did Syros Pharmaceuticals IPO?

Syros Pharmaceuticals (SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (13.05%), Avidity Partners Management LP (7.94%), Blue Owl Capital Holdings LP (7.09%), Point72 Asset Management L.P. (6.99%), Flagship Pioneering Inc. (6.14%) and Vanguard Group Inc. (3.63%). Insiders that own company stock include David Roth, Eric R Olson, Srinivas Akkaraju and Timothy Tyson.
View institutional ownership trends
.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SYRS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners